Evaluation of residual tin in synthesized aliphatic biomedical polyesters by electrothermal atomic absorption spectroscopy

Abstract

Oznaczanie pozosta³ooeci cyny w syntetyzowanych biomedycznych poliestrach alifatycznych metod¹ elektrotermicznej absorpcyjnej spektrometrii atomowej Streszczenie-Metod¹ polimeryzacji z otwarciem pieroecienia, katalizowanej 2-etyloheksanianem cyny (SnOct 2) otrzymano cykliczne poliestry: polilaktyd (PLA) i poli(e-kaprolakton) (PCL). Uzyskane produkty poddawano procesowi kilkakrotnego oczyszczania z pozosta³ooeci cynoorganicznego katalizatora. Zawartooeae Sn w polimerach, po ka¿dym kolejnym oczyszczaniu, oznaczano za pomoc¹ elektrotermicznej absorpcyjnej spektrometrii atomowej (ET-AAS). Wyniki analiz dyskutowano uwzglêdniaj¹c wymagania Farmakopei Europejskiej dotycz¹ce dopuszczalnej zawartooeci cyny w biomedycznych poliestrach alifatycznych. Stwierdzono, ¿e czterokrotne oczyszczanie produktu polireakcji pozwala na obni¿enie poziomu stê¿enia Sn o 3 rzêdy wielkooeci, do wartooeci mniejszych ni¿ okreoelone przez Farmakopeê dla materia³ów maj¹cych kontakt z krwi¹, ponadto operacje te nie powoduj¹ degradacji polimeru. S³owa kluczowe: poliestry alifatyczne, polilaktyd, poli(e-kaprolakton), polimery biomedyczne, elektrotermiczna absorpcyjna spektrometria atomowa. DETERMINATION OF RESIDUAL TIN IN SYNTHESIZED ALIPHATIC BIOMEDICAL POLY-ESTERS BY ELECTROTHERMAL ATOMIC ABSORPTION SPECTROSCOPY Summary-The synthesis of the aliphatic polyesters-polylactide (PLA) and poly (e-caprolactanes) (PCL) in the ring-opening polymerization of cyclic esters in the presence tin(II) 2-ethylhexanoate (SnOct 2) has been presented. The obtained products were subjected to multiple purification procedures to remove residual organo-tin catalyst (Tables 2 and 3). The tin content in the polyesters was then determined by Electrothermal Atomic Absorption Spectroscopy (ET-AAS) (Tables 3 and 4) after each purification process. The results of the analysis were discussed taking into consideration the requirements placed by the European Pharmacopoeia regarding the amount of tin allowed in aliphatic biomedical polyesters. It was confirmed, that a four-stage purification of the polyreaction product led to a threefold decrease in the concentration of tin to a level less than the value required by Pharmacopoeia for materials designated for contact with blood. Moreover, the purification process did not generate any degradation of the polymer.

AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia

“…Furthermore, the commercial biomedical PURs are usually prepared by the polyaddition process catalyzed by organic‐metal compounds (mainly Sn) 17–22. Organic compounds of Zn, Al, and Sn are very effective in ROP or polyaddition process, but most of them are toxic for human 23, 24…”

Segmented polyurethane elastomers derived from aliphatic polycarbonate and poly(ester‐carbonate) soft segments for biomedical applications

“…[17][18][19][20][21][22] Organic compounds of Zn, Al, and Sn are very effective in ROP or polyaddition process, but most of them are toxic for human. 23,24 Recently, natural initiators and catalysts have attracted much attention because of the potential toxicity of the polymers catalyzed by organic-metal compounds. Among them, the application of enzymes in ROP has been actively pursued in the last years.…”

Biocompatible Catalysts for Lactide Polymerization—Catalyst Activity, Racemization Effect, and Optimization of the Polymerization Based On Design of Experiments

“…4 Nontoxic and biocompatible PLA can be used in regenerative medicine for damaged tissues. Also, PLA has found many applications: packaging materials, 1,5 textiles, 6 and composites. 68 Medicine 7,8 and pharmacy 9,10 are continually looking for new applications for polylactide.…”